Ann: Quarterly Activities Report and Appendix 4C - December 2018, page-65

Ok, so your exclusive focus is on the share price as opposed to the business. Not knowing what goes on behind the scenes as far as how said media has or might affect approaches, leads, prospective trials and the like. But that $20k promotion will suddenly solve the problem because independent research at the spec end of the market is the watershed for integrity (despite being paid for). Take aim at Pac if you must since they've got the promotion gig. The deals though, I'm still not getting the critique given the fascination with what isn't all that much better/exciting. And I'm open to considering management alternatives, if any competent ones were interested